PharmaEssentia Corporation
6446
Peringkat dalam Saham
#1440
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Harga Saham
$36.89
Kapitalisasi Pasar
$15.25B
Perubahan (1 hari)
-1.28%
Perubahan (1 tahun)
144.12%
Negara
TW
Perdagangan PharmaEssentia Corporation (6446)
Kategori
Healthcare
Laba untuk PharmaEssentia Corporation (6446)
Laba pada Jun 2026 TTM: $284.95M
Menurut laporan keuangan terbaru dari PharmaEssentia Corporation, laba saat ini perusahaan adalah $284.95M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-32.16M, peningkatan dibandingkan laba tahun 2022 sebesar $-60.07M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk PharmaEssentia Corporation dari 2010 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $284.95M | 212.31% |
| 2024 | $91.24M | -383.66% |
| 2023 | $-32.16M | -46.45% |
| 2022 | $-60.07M | -40.77% |
| 2021 | $-101.42M | 46.26% |
| 2020 | $-69.34M | 146.30% |
| 2019 | $-28.15M | -17.15% |
| 2018 | $-33.98M | 15.54% |
| 2017 | $-29.41M | 12.91% |
| 2016 | $-26.05M | 0.49% |
| 2015 | $-25.92M | -3.64% |
| 2014 | $-26.90M | 35.45% |
| 2013 | $-19.86M | 125.31% |
| 2012 | $-8.81M | 31.09% |
| 2011 | $-6.72M | 17.15% |
| 2010 | $-5.74M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 519.26% |
IN
|
